InVivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

87Citations
Citations of this article
176Readers
Mendeley users who have this article in their library.

Abstract

We used an invivo small hairpin RNA (shRNA) screening approach to identify genes that are essential for MLL-AF9 acute myeloid leukemia (AML). We found that Integrin Beta 3 (Itgb3) is essential for murine leukemia cells invivo and for human leukemia cells in xenotransplantation studies. In leukemia cells, Itgb3 knockdown impaired homing, downregulated LSC transcriptional programs, and induced differentiation via the intracellular kinase Syk. In contrast, loss of Itgb3 in normal hematopoietic stem and progenitor cells did not affect engraftment, reconstitution, or differentiation. Finally, using an Itgb3 knockout mouse model, we confirmed that Itgb3 is dispensable for normal hematopoiesis but is required for leukemogenesis. Our results establish the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML. © 2013 Elsevier Inc.

Cite

CITATION STYLE

APA

Miller, P. G., Al-Shahrour, F., Hartwell, K. A., Chu, L. P., Järås, M., Puram, R. V., … Ebert, B. L. (2013). InVivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. Cancer Cell, 24(1), 45–58. https://doi.org/10.1016/j.ccr.2013.05.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free